Randomized, Open-Label, Blinded-Endpoint, Crossover, Single Dose Study to Compare the Pharmacodynamics of Torasemide-PR 10 mg, Torasemide-IR 10 mg and Furosemide-IR 40 mg, in Patients With Compensated Heart Failure.
Phase of Trial: Phase IV
Latest Information Update: 24 Apr 2013
At a glance
- Drugs Torasemide (Primary) ; Furosemide
- Indications Heart failure
- Focus Pharmacodynamics
- Sponsors Ferrer
- 26 May 2012 New source identified and integrated: Clinical Trials Database record EudaCT2011-000972-32.
- 15 Mar 2012 New trial record